Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Ingenium gets FDA Greenlight for Phase 2 Gengleucel Trial in MRD+ AML
Details : IGNK001 (gengleucel) is positioned to become the first NK cell therapy in AML having potential to improve outcomes by eradicating minimal residual disease and reducing relapse risk.
Product Name : IGNK001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 30, 2025
Reset All
